HAYWARD, Calif.--Lynx Therapeutics announced that it will collaborate with Oxagen of Oxford, UK, to discover and validate disease-associated single-nucleotide polymorphisms (SNPs). The program will initially focus on inflammatory bowel disease, but may be extended to other common disorders. No financial terms were disclosed.
Lynx will apply its proprietary SNP-extracting and genotyping technologies to identify disease-associated SNPs from large, well characterized patient populations available to Oxagen through its clinical collaborators. Oxagen will map and further refine the regions of association defined by these SNPs to locate disease genes and identify functional polymorphisms within them.